162 related articles for article (PubMed ID: 28560953)
1. Nelfinavir and Ritonavir Kill Bladder Cancer Cells Synergistically by Inducing Endoplasmic Reticulum Stress.
Sato A; Asano T; Okubo K; Isono M; Asano T
Oncol Res; 2018 Mar; 26(2):323-332. PubMed ID: 28560953
[TBL] [Abstract][Full Text] [Related]
2. The Dual Histone Deacetylase-Proteasome Inhibitor RTS-V5 Acts Synergistically With Ritonavir to Induce Endoplasmic Reticulum Stress in Bladder Cancer Cells.
Okubo K; REßING N; Schulz WA; Hansen FK; Asano T; Sato A
Anticancer Res; 2021 Dec; 41(12):5987-5996. PubMed ID: 34848452
[TBL] [Abstract][Full Text] [Related]
3. Panobinostat and Nelfinavir Inhibit Renal Cancer Growth by Inducing Endoplasmic Reticulum Stress.
Okubo K; Isono M; Asano T; Sato A
Anticancer Res; 2018 Oct; 38(10):5615-5626. PubMed ID: 30275179
[TBL] [Abstract][Full Text] [Related]
4. Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation.
Sato A; Asano T; Okubo K; Isono M; Asano T
Cancer Sci; 2017 Jun; 108(6):1194-1202. PubMed ID: 28342223
[TBL] [Abstract][Full Text] [Related]
5. Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.
Sato A; Asano T; Ito K; Asano T
Urology; 2012 Apr; 79(4):966.e13-21. PubMed ID: 22296623
[TBL] [Abstract][Full Text] [Related]
6. Ritonavir Interacts With Belinostat to Cause Endoplasmic Reticulum Stress and Histone Acetylation in Renal Cancer Cells.
Isono M; Sato A; Okubo K; Asano T; Asano T
Oncol Res; 2016; 24(5):327-335. PubMed ID: 27712589
[TBL] [Abstract][Full Text] [Related]
7. Lopinavir-Ritonavir Combination Induces Endoplasmic Reticulum Stress and Kills Urological Cancer Cells.
Okubo K; Isono M; Asano T; Sato A
Anticancer Res; 2019 Nov; 39(11):5891-5901. PubMed ID: 31704813
[TBL] [Abstract][Full Text] [Related]
8. Nelfinavir Induces Endoplasmic Reticulum Stress and Sensitizes Renal Cancer Cells to TRAIL.
Okubo K; Sato A; Isono M; Asano T; Asano T
Anticancer Res; 2018 Aug; 38(8):4505-4514. PubMed ID: 30061216
[TBL] [Abstract][Full Text] [Related]
9. Delanzomib Interacts with Ritonavir Synergistically to Cause Endoplasmic Reticulum Stress in Renal Cancer Cells.
Isono M; Sato A; Asano T; Okubo K; Asano T
Anticancer Res; 2018 Jun; 38(6):3493-3500. PubMed ID: 29848702
[TBL] [Abstract][Full Text] [Related]
10. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.
Gills JJ; Lopiccolo J; Tsurutani J; Shoemaker RH; Best CJ; Abu-Asab MS; Borojerdi J; Warfel NA; Gardner ER; Danish M; Hollander MC; Kawabata S; Tsokos M; Figg WD; Steeg PS; Dennis PA
Clin Cancer Res; 2007 Sep; 13(17):5183-94. PubMed ID: 17785575
[TBL] [Abstract][Full Text] [Related]
11. Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition.
Kim JY; Park YJ; Lee BM; Yoon S
Anticancer Res; 2019 Jul; 39(7):3757-3765. PubMed ID: 31262902
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells.
Brüning A; Friese K; Burges A; Mylonas I
Breast Cancer Res; 2010; 12(4):R45. PubMed ID: 20594311
[TBL] [Abstract][Full Text] [Related]
13. Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies.
Mahoney E; Maddocks K; Flynn J; Jones J; Cole SL; Zhang X; Byrd JC; Johnson AJ
Leuk Lymphoma; 2013 Dec; 54(12):2685-92. PubMed ID: 23469959
[TBL] [Abstract][Full Text] [Related]
14. Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulation.
Brüning A; Rahmeh M; Friese K
Mol Oncol; 2013 Dec; 7(6):1012-8. PubMed ID: 23916134
[TBL] [Abstract][Full Text] [Related]
15. Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1.
Chow WA; Guo S; Valdes-Albini F
Anticancer Drugs; 2006 Sep; 17(8):891-903. PubMed ID: 16940799
[TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity.
Fukuda Y; Takenaka K; Sparreboom A; Cheepala SB; Wu CP; Ekins S; Ambudkar SV; Schuetz JD
Mol Pharmacol; 2013 Sep; 84(3):361-71. PubMed ID: 23775562
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.
Kawabata S; Gills JJ; Mercado-Matos JR; Lopiccolo J; Wilson W; Hollander MC; Dennis PA
Cell Death Dis; 2012 Jul; 3(7):e353. PubMed ID: 22825471
[TBL] [Abstract][Full Text] [Related]
18. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
Washington CB; Duran GE; Man MC; Sikic BI; Blaschke TF
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):203-9. PubMed ID: 9803961
[TBL] [Abstract][Full Text] [Related]
19. Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells.
Okubo K; Isono M; Miyai K; Asano T; Sato A
Cancer Sci; 2020 Jan; 111(1):112-126. PubMed ID: 31675763
[TBL] [Abstract][Full Text] [Related]
20. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis.
Kraus M; Malenke E; Gogel J; Müller H; Rückrich T; Overkleeft H; Ovaa H; Koscielniak E; Hartmann JT; Driessen C
Mol Cancer Ther; 2008 Jul; 7(7):1940-8. PubMed ID: 18645004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
